U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556120) titled 'Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)' on April 16.
Brief Summary: This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
Study Start Date: May 05
Study Type: INTERVENTIONAL
Condition:
Generalized Myasthenia Gravis
Intervention:
DRUG: HN2301 injection
Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shenzhen MagicRNA Biotechnology C...